Search Within

Craig Moskowitz

  1. "Advanced Practice Providers"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (10)
Groups
  1. Advanced Practice Providers (27)
  2. Department of Medicine (27)
  3. Hematologic Malignancies, Division of (27)
  4. Center for Hematologic Malignancies (25)
  5. Lymphoma (24)
  6. Survivorship Research (23)

More Groups

People
  1. Andrew Zelenetz (21)
  2. Matthew Matasar (20)
  3. Alison Moskowitz (18)
  4. John Gerecitano (17)
  5. Ariela Noy (16)
  6. David Straus (16)

More People

Years
  1. 2021 (2)
  2. 2020 (1)
  3. 2019 (1)
  4. 2018 (2)
  5. 2017 (4)
  6. 2016 (3)

More Years

Publications
  1. Blood (11)
  2. Journal of Clinical Oncology (5)
  3. Annals of Oncology (3)
  4. Biology of Blood and Marrow Transplantation (2)
  5. Hematological Oncology (2)
  6. British Journal of Haematology (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (3)
  4. Oxford University Press (3)
  5. Wiley Blackwell (2)
  6. Elsevier Science, Inc. (1)

More Publishers

Results (27)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Noninvasive monitoring of mantle cell lymphoma by immunoglobulin gene next-generation sequencing in a phase 2 study of sequential chemoradioimmunotherapy followed by autologous stem-cell rescue
    Journal Article

    Kumar, A.; Bantilan, K. S.; Jacob, A. P.; Park, A.; Schoninger, S. F.; Sauter, C.; Ulaner, G. A.; Casulo, C.; Faham, M.; Kong, K. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Efficacy of revaccination after autologous hematopoietic stem cell transplantation in lymphoma patients with or without rituximab exposure
    Meeting Abstract

    Preston, E. V.; Palazzo, M.; Seier, K.; Maloy, M. A.; Devlin, S. M.; Giralt, S. A.; Scordo, M.; Dahi, P. B.; Matasar, M. J.; Moskowitz, C. H.; more...
    Biology of Blood and Marrow Transplantation (2019)

    Fulltext@MSK | Save
  • Initial results of a phase II study of sequential chemotherapy and lenalidomide followed by rituximab and lenalidomide maintenance for untreated mantle cell lymphoma
    Meeting Abstract

    Kumar, A.; Zelenetz, A. D.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; Hamlin, P. A.; Laraque, L.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL
    Journal Article

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Devlin, S. M.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma
    Journal Article

    Bröckelmann, P. J.; Müller, H.; Casasnovas, O.; Hutchings, M.; von Tresckow, B.; Jürgens, M.; McCall, S. J.; Morschhauser, F.; Fuchs, M.; Borchmann, P.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma
    Meeting Abstract

    Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save